Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|July 29, 2026 (Updated: July 29, 2026)

The BioPharm Brief: Designations, Decisions, and Data

Listen
0:00 / 0:00

Today's episode explores how FDA expedited pathways continue to shape advanced therapy development, from new RMAT designations for cell and gene therapies to an advisory committee review that underscores the agency's evolving expectations for clinical evidence.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today's stories all focus on one theme: how FDA expedited programs can accelerate innovation while still demanding strong clinical evidence.

First, Allogene Therapeutics announced that its investigational allogeneic CAR-T therapy, cema-cel, has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from FDA for first-line consolidation treatment of patients with large B-cell lymphoma who remain minimal residual disease positive after initial therapy. The dual designations are intended to support more frequent interactions with FDA and potentially accelerate development and review as the company advances its pivotal ALPHA3 study.

Next, Ocugen's modifier gene therapy OCU410 received FDA RMAT designation for the treatment of geographic atrophy secondary to dry age-related macular degeneration. The designation follows encouraging clinical data and recent alignment with FDA on the design of the planned Phase 3 registrational trial. RMAT status is designed specifically for regenerative medicine therapies and may provide opportunities for enhanced regulatory engagement throughout development.

Finally, an FDA advisory committee is preparing to review Replimune's biologics license application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma. Ahead of the meeting, FDA briefing documents questioned whether the available single-arm data provide sufficient evidence of efficacy, citing concerns about trial design and the inability to clearly determine RP1's contribution to treatment response. The review highlights the agency's continued emphasis on robust clinical evidence, even for therapies seeking expedited regulatory pathways.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Takeaways

  • FDA granted new expedited designations to both an allogeneic CAR-T therapy and a modifier gene therapy, reflecting continued momentum for advanced therapies.
  • RMAT and Fast Track programs remain important tools for accelerating development while facilitating closer interaction with regulators.
  • An upcoming FDA advisory committee meeting for RP1 illustrates that expedited programs do not lessen expectations for well-controlled clinical evidence.

Related to this article

View more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more